Rusnano asset launches UK sales of new osteoarthritis pain reliever

A joint Russo-British biopharmaceutical project has launched sales of its innovation drug-free pain-relieving product for osteoarthritis patients in the United Kingdom

Pro Bono Bio, a joint Russo-British biopharmaceutical project, has launched sales of its innovation drug-free pain-relieving product for osteoarthritis patients in the United Kingdom, the Rusnano website reported. Pro Bono Bio is the JV between Rusnano, Russia?s nanotech giant, and Celtic Pharma, a UK investment fund. The project was launched in Moscow in 2011. The developer has successfully completed a series of rigorous tests aided by Arthritis Research UK, a British foundation. The product, called Flexiseq, is said to have proved ?high efficiency and safety compared to existing methods of medication-based treatment of osteoarthritis symptoms.? With its innovation mechanism of targeted physical protection of damaged human tissues the new approach requires no use of active pharmaceutical components. As it contains no drugs, it is not expected to cause any drug-to-drug interactions, and has no contra-indications, Rusnano reported. This is particularly important when treating elderly patients who are most at risk for the disease...